A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies

CAR T-cell therapies hold great promise for treating a range of malignancies but are however challenged by the complexity of their production and by the adverse events related to their activity. Here we report the development of the CubiCAR, a tri-functional CAR architecture that enables CAR T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Valton, Julien, Guyot, Valerie, Boldajipour, Bijan, Sommer, Cesar, Pertel, Thomas, Juillerat, Alexandre, Duclert, Aymeric, Sasu, Barbra Johnson, Duchateau, Philippe, Poirot, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997667/
https://www.ncbi.nlm.nih.gov/pubmed/29895885
http://dx.doi.org/10.1038/s41598-018-27264-w
Descripción
Sumario:CAR T-cell therapies hold great promise for treating a range of malignancies but are however challenged by the complexity of their production and by the adverse events related to their activity. Here we report the development of the CubiCAR, a tri-functional CAR architecture that enables CAR T-cell detection, purification and on-demand depletion by the FDA-approved antibody Rituximab. This novel architecture has the potential to streamline the manufacturing of CAR T-cells, allow their tracking and improve their overall safety.

Ejemplares similares